Clinical trial • Phase III • Oncology
LY3484356 for Breast cancer|Endometrial cancer
Phase III trial of LY3484356 for Breast cancer|Endometrial cancer. 49 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Breast cancer|Endometrial cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 14-02-2024
- First CTIS Authorization Date
- 26-04-2024
Trial design
Phase III trial across 12 sites in Spain, France, Belgium.
- Target Sample Size
- 49
Recruitment
- Planned Sample Size
- 49
- Recruitment Window Months
- 21
Geography
- Total Number Of Sites
- 12
- Total Number Of Participants
- 12
Spain
- Earliest CTIS Part Ii Submission Date
- 13-12-2023
- Latest Decision Or Authorization Date
- 26-04-2024
- Processing Time Days
- 135
- Number Of Sites
- 6
- Number Of Participants
- 7
Sites
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Oncology
- Principal Investigator Name
- Elena Lopez Miranda
- Principal Investigator Email
- elemiranda@hotmail.com
- Contact Person Name
- Elena Lopez Miranda
- Contact Person Email
- elemiranda@hotmail.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Oncology
- Principal Investigator Name
- Irene Moreno Candilejo
- Principal Investigator Email
- irene.moreno@startmadrid.com
- Contact Person Name
- Irene Moreno Candilejo
- Contact Person Email
- irene.moreno@startmadrid.com
- Site Name
- Hospital Clinico San Carlos
- Department Name
- Oncology
- Principal Investigator Name
- Jose Angel Garcia Saenz
- Principal Investigator Email
- jgsaenz@salud.madrid.org
- Contact Person Name
- Jose Angel Garcia Saenz
- Contact Person Email
- jgsaenz@salud.madrid.org
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncology
- Principal Investigator Name
- Luis Manso Sanchez
- Principal Investigator Email
- luismansosanchez@gmail.com
- Contact Person Name
- Luis Manso Sanchez
- Contact Person Email
- luismansosanchez@gmail.com
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Haematological and Oncological diseases
- Principal Investigator Name
- Ivan Manuel Victoria Ruiz
- Principal Investigator Email
- ivictori@recerca.clinic.cat
- Contact Person Name
- Ivan Manuel Victoria Ruiz
- Contact Person Email
- ivictori@recerca.clinic.cat
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- Oncology
- Principal Investigator Name
- Joaquin Gavila Gregori
- Principal Investigator Email
- jgavila@fivo.org
- Contact Person Name
- Joaquin Gavila Gregori
- Contact Person Email
- jgavila@fivo.org
France
- Earliest CTIS Part Ii Submission Date
- 13-12-2023
- Latest Decision Or Authorization Date
- 02-05-2024
- Processing Time Days
- 141
- Number Of Sites
- 3
- Number Of Participants
- 3
Sites
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Oncologie Médicale
- Principal Investigator Name
- Mario Campone
- Principal Investigator Email
- mario.campone@ico.unicancer.fr
- Contact Person Name
- Mario Campone
- Contact Person Email
- mario.campone@ico.unicancer.fr
- Site Name
- Institut Curie
- Department Name
- Oncology medical Department
- Principal Investigator Name
- Jean-Yves Pierga
- Principal Investigator Email
- jean-yves.pierga@curie.fr
- Contact Person Name
- Jean-Yves Pierga
- Contact Person Email
- jean-yves.pierga@curie.fr
- Site Name
- Institut De Cancerologie Strasbourg Europe
- Principal Investigator Name
- Lauriane EBERST
- Principal Investigator Email
- l.eberst@icans.eu
- Contact Person Name
- Lauriane EBERST
- Contact Person Email
- l.eberst@icans.eu
Belgium
- Earliest CTIS Part Ii Submission Date
- 13-12-2023
- Latest Decision Or Authorization Date
- 30-04-2024
- Processing Time Days
- 139
- Number Of Sites
- 3
- Number Of Participants
- 2
Sites
- Site Name
- Institut Jules Bordet
- Department Name
- Clinical Trial Conduct Unit
- Principal Investigator Name
- Philippe Aftimos
- Principal Investigator Email
- philippe.aftimos@hubruxelles.be
- Contact Person Name
- Philippe Aftimos
- Contact Person Email
- philippe.aftimos@hubruxelles.be
- Site Name
- UZ Leuven
- Department Name
- Gynecologic Oncology
- Principal Investigator Name
- Patrick Neven
- Principal Investigator Email
- patrick.neven@uzleuven.be
- Contact Person Name
- Patrick Neven
- Contact Person Email
- patrick.neven@uzleuven.be
- Site Name
- Antwerp University Hospital
- Department Name
- Oncology
- Principal Investigator Name
- Hans Prenen
- Principal Investigator Email
- hans.prenen@uza.be
- Contact Person Name
- Hans Prenen
- Contact Person Email
- hans.prenen@uza.be
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY3484356
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)